US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
pharma · Colonic disease
Norgine
Norgine Pty.
Norgine drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Amsterdam, NL HQ
1906 Founded
1,160 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Amsterdam, NL
- Founded
- 1906
- Employees
- 1,160
- Programs
- 1
- Drugs
- 3
- Patents
- 0
Norgine pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Norgine drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
eflornithine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Norgine's portfolio. Mechanism: Ornithine decarboxylase inhibitor.
- Mechanism
- Ornithine decarboxylase inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA-directed RNA polymerase.
- Target
- Bacterial DNA-directed RNA polymerase
- Mechanism
- Bacterial DNA-directed RNA polymerase inhibitor